Yahoo Web Search

Search results

1. • 

     Cheaper competition for Humira is hitting the market, but savings will depend on your insurance

     AP Finance via Yahoo Finance· 11 months ago

     Patients who take the autoimmune disease treatment Humira may see some price relief when several...

2. • 

     AbbVie's Humira gets a U.S. rival, but costs could stay high

     Reuters via Yahoo Finance· 1 year ago

     U.S. patients will finally get access to cheaper versions of AbbVie Inc’s blockbuster arthritis drug...

3. • 

     How Horizon Therapeutics sold to Amgen for $27.8 billion without ever licensing a drug of its own

     Fortune via Yahoo Finance· 1 year ago

     The new drug looked so promising—except for that one warning sign. At the American College of...

4. • 

     Why Investors Should Care About Novartis' Latest Label Expansion -- It Could Mean Billions

     Motley Fool· 11 months ago

     Earlier this month, Novartis' (NYSE: NVS) smash-hit immunology medicine Cosentyx became the first...

5. • 

     Here's What This Drug News Could Mean for AbbVie's Shareholders

     Motley Fool· 2 years ago

     On May 11, AbbVie (NYSE: ABBV) announced positive top-line results in its phase 3 clinical trial of...

6. • Good news for consumers, bad news for North Chicago-based AbbVie as its blockbuster drug Humira...

     Chicago Tribune via Yahoo News· 1 year ago

     One of the most popular prescription medications in the world is about to face fierce competition in the U.S. — something that could mean lower prices for the drug but a difficult coming year ...

7. • 

     Obesity drugs like Ozempic are costly, but here’s how we’ll save money down the line | Opinion

     Fort Worth Star-Telegram via Yahoo News· 10 months ago

     New weight loss drugs powerful enough to help obese patients lose up to a fifth of their total body...

8. • 

     This Blockbuster Drug's Latest News Could Be Another Home Run for AbbVie

     Motley Fool· 1 year ago

     AbbVie (NYSE: ABBV) recently shared positive top-line results from its phase 3 clinical trial of...

9. • 

     Amgen Inc. (NASDAQ:AMGN) Q4 2022 Earnings Call Transcript

     Insider Monkey via Yahoo Finance· 1 year ago

     Amgen Inc. (NASDAQ:AMGN) Q4 2022 Earnings Call Transcript January 31, 2023 Amgen Inc. misses on...

10. • 

      This Blockbuster Drug from AbbVie Is Closer to Another Major Indication

      Motley Fool· 2 years ago

      The European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) recently...